HBM Sells Swixx Biopharma to SK Capital for €1.5bn
Swiss-listed HBM Healthcare Investments has agreed to sell a majority stake in Swixx Biopharma, a specialised distributor of rare diseases, prescription and over the counter medicinal products to US-based SK Capital Partners. This marks a strategic milestone for both parties as the pharma commercialisation platform accelerates global expansion. The transaction, valued at over €1.5bn, will see HBM, Swixx’s founders, and co-investors…